StockNews.com upgraded shares of ProPhase Labs (NASDAQ:PRPH – Free Report) to a sell rating in a research note published on Wednesday morning.
ProPhase Labs Stock Down 1.4 %
NASDAQ:PRPH opened at $4.26 on Wednesday. ProPhase Labs has a 12-month low of $4.05 and a 12-month high of $7.59. The company has a quick ratio of 1.73, a current ratio of 1.88 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $81.28 million, a P/E ratio of -3.94 and a beta of -0.18. The stock’s fifty day simple moving average is $4.92 and its 200-day simple moving average is $5.10.
ProPhase Labs (NASDAQ:PRPH – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.21. ProPhase Labs had a negative return on equity of 44.96% and a negative net margin of 82.18%. The business had revenue of $3.63 million for the quarter, compared to analyst estimates of $9.86 million. During the same period last year, the company earned $0.03 EPS. Equities research analysts expect that ProPhase Labs will post -0.82 earnings per share for the current year.
Institutional Inflows and Outflows
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Stories
- Five stocks we like better than ProPhase Labs
- Transportation Stocks Investing
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- ESG Stocks, What Investors Should Know
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Most Volatile Stocks, What Investors Need to Know
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.